Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...
Eli Lilly and Company LLY announced that the European Medicines Agency's Committee for Medicinal Products for Human Use ...
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year ...
Hosted on MSN2d
CHMP recommends AbbVie’s Rinvoq be approved for adult GCAThe treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, ...
Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...
Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study1,2 DLBCL—an ...
If granted, IXCHIQ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and ...
About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie's upadacitinib (Rinvoq) to treat adults with giant cell arteritis (GCA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback